Effect of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Women: A Randomized Clinical Trial.

ABSTRACT:

Importance

The prevention of chemotherapy-induced nausea and vomiting has an important role in the overall management of cancer treatment.

Objective

To evaluate whether adding aprepitant to palonosetron and dexamethasone can further prevent the incidence and severity of nausea and vomiting caused by FOLFIRI (fluorouracil, leucovorin, and irinotecan) or FOLFOX (fluorouracil, leucovorin, and oxaliplatin) chemotherapy regimens among women with gastrointestinal cancer at higher risk.

Design, setting, and participants

This phase 3, double-blind, placebo-controlled randomized clinical trial recruited young women (age ≤50 years) who drank little or no alcohol and had gastrointestinal cancer for which they received FOLFOX or FOLFIRI chemotherapy. A total of 248 women were enr

SUBMITTER: Wang DS 

PROVIDER: S-EPMC8035650 | biostudies-literature | 2021 Apr

REPOSITORIES: biostudies-literature